- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04180995
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma
This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma.
Primary objective: To evaluate pathological response (pCR+pPR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.
The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Chuanliang Cui, Dr
- Phone Number: '+8613691489319
- Email: 1008ccl@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being voluntary to sign the informed consent form, with good compliance and willingness to cooperate with follow-up;
- Age of 18-75 years, male or female;
- Histopathologically diagnosed mucosal melanoma;
- ECOG PS score 0 or 1;
- Being considered to be able to be completely resected after multidisciplinary (including surgeon, oncologist and radiologist) discussion, and systemic staging examination improved prior to enrollment (need to include cranial enhanced CT/MRI, bone scan, thoracic, abdominal and pelvic enhanced CT/MRI (enhanced MRI of head and neck, gynecological examination additionally needed for female genital melanoma, colonoscopy additionally needed for rectal melanoma), B mode ultrasonography of superficial lymph node, or systemic PET-CT) demonstrated no regional or distant metastasis;
No contraindications for the treatment, including normal peripheral hemogram, basically normal hepatic and renal function as well as ECG:
- Peripheral hemogram: white blood cell (WBC) ≥3.5×109/L, neutrophil (ANC) ≥1.5×109/L, platelet (PLT) ≥100×109/L, hemoglobin (Hgb) ≥90 g/L;
- Liver function: alanine aminotransferase (ALT) ≤1.5×ULN, aspartate aminotransferase (AST) ≤1.5×ULN, and total bilirubin (TBil) ≤1.5×ULN;
- Renal function: blood urea nitrogen ≤ ULN, creatinine ≤ ULN;
- Use of highly-effective contraceptive methods during the whole study for men of reproduction ability or women of pregnant possibility (e.g. oral contraceptives, intrauterine contraceptive device, abstinence of sexual intercourse or barrier contraception in combination with spermatocide), and continuation of contraception for 12 months after the end of study treatment.
Exclusion Criteria:
- Previously treated with anti-PD-1, anti-PD-L1, anti-PD-L2, or antiangiogenic drugs;
- Known allergy to Toripalimab or Axitinib or excipient of the study drug;
- Patients with ocular melanoma or melanoma with unknown primary foci;
- Pregnant and breastfeeding women;
- Abnormal coagulation function [activated partial thromboplastin time (APTT)> 43 s, or international normalized ratio (INR) > 1.5×ULN], or hemorrhagic tendency or hemorrhagic event occurred within two months prior to enrollment (e.g., gastrointestinal hemorrhage, hemorrhagic gastric ulcer, etc.), or receiving thrombolytic or anticoagulation therapy;
- Currently having serious and uncontrolled acute infection, or suppurative infection, chronic infection, or prolonged wound healing;
- Having serious heart disease, including congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction, severe valvular heart disease and refractory hypertension;
- Having neurological, mental disease or psychiatric disorder that can not be easily controlled, poor compliance, inability to cooperate and narrate therapeutic response;
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Concomitantly other Malignancies;
- Concomitant participation in other clinical trials;
- Positive HIV antibody, or positive HCV antibody/HCV-RNA, or positive HBsAg or HBcAb whilst HBV DNA copy >2000 IU/ml;
- Active autoimmune diseases requiring systemic treatment in the past two years (e.g., use of disease-regulating drug, corticosteroid or immunosuppressant), relevant replacement therapy is allowed (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for renal or pituitary insufficiency);
- Vaccination of live vaccine within 4 weeks prior to the start of study;
- Other severe, acute or chronic medical diseases or abnormalities in laboratory examination possibly increasing the relevant risk in study participation or possibly interfering the interpretation of study results as judged by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab, Axitinib
The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib.
Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
|
TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological response (pCR+pPR) rate: defined as the percentage of subjects without alive tumor cells and alive tumor cells in postoperative resected specimens 10% - 50% in the resected specimen post operation.
Time Frame: Approximately 8 weeks
|
To evaluate pathological response (pCR+pPR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.
|
Approximately 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AEs/SAEs
Time Frame: Approximately 2 years
|
Adverse events (AEs) ; serious adverse events (SAEs); abnormal value of Lab test according to NCI-CTCAE V5.0
|
Approximately 2 years
|
RFS (recurrence-free survival) per RECIST1.1 as Assessed by investigator
Time Frame: Approximately 1 years
|
To evaluate recurrence-free survival (RFS) of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.
|
Approximately 1 years
|
OS (overall survival)
Time Frame: Approximately 2 years
|
OS at 1 or 2 years.
|
Approximately 2 years
|
Pathological complete response (pCR) rate: defined as the percentage of subjects without alive tumor cells in the resected specimen post operation.
Time Frame: Approximately 8 weeks
|
To evaluate pathological complete response (pCR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.
|
Approximately 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD-L1 expression
Time Frame: 2 years
|
Correlation between predictive biomarkers and efficacy, including PD-L1 expression.
|
2 years
|
CD3 and CD8 gene mutation
Time Frame: 2 years
|
Correlation between predictive biomarkers and efficacy, including CD3 and CD8, gene mutation status, etc.
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS001-ISS-132
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucosal Melanoma
-
National Cancer Institute (NCI)RecruitingMucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditionsUnited States, Canada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...United States
-
Viewpoint Molecular TargetingMayo ClinicCompletedMelanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, MucosalUnited States
-
Hoffmann-La RocheCompletedUveal Melanoma | Cutaneous Melanoma | Mucosal MelanomaSpain, United States, Belgium, Denmark, Canada, Australia
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Eye & ENT Hospital of Fudan UniversityCancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingMucosal Melanoma | Sinonasal MelanomaChina
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
Craig L Slingluff, JrUniversity of VirginiaCompletedMelanoma | Metastatic Melanoma | Mucosal MelanomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's HospitalCompletedMelanoma | Acral Melanoma | Mucosal Lentiginous MelanomaUnited States
Clinical Trials on TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Shanghai Junshi Bioscience Co., Ltd.CompletedTreatment-naive Advanced Non-small Cell Lung CancerChina
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Ascentage Pharma Group Inc.Recruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingAdvanced Hepatocellular CarcinomaChina
-
University of California, San DiegoThe Cleveland ClinicUnknownClear Cell Renal Cell CarcinomaUnited States
-
Wan HeRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingHepatocellular CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Nasopharyngeal CarcinomaChina